Is polycystic ovarian morphology related to a poor oocyte quality after controlled ovarian hyperstimulation for intracytoplasmic sperm injection Results from a prospective comparative study

A comparison of controlled ovarian hyperstimulation outcomes between patients with polycystic ovarian morphology and concurrently treated and age-matched controls does not reveal any difference regarding oocyte quality.

Julien Sigala, Pharm.D., Christophe Sifer, M.D., Didier Dewailly, M.D., Geoffroy Robin, M.D., Aude Bruyneel, M.D., Nassima Ramdane, B.S.T., Valérie Lefebvre-Khalil, M.D., Valérie Mitchell, Pharm.D., Ph.D., Christine Decanter, M.D.

Volume 103, Issue 1, Pages 112-118


To evaluate the relationship between polycystic ovarian morphology (PCOM) and oocyte quality after controlled ovarian stimulation for intracytoplasmic sperm injection (ICSI).

Prospective, comparative study with concurrently treated and age-matched controls.

Academic IVF unit of the Lille University Hospital.

A total of 194 women were prospectively included before their first IVF-ICSI attempt for exclusive male infertility. They were classified into PCOM (n = 97) or control groups (n = 97) according to their follicle number per ovary. The nuclear maturation and morphologic aspects of 1,013 oocytes from PCOM patients were assessed and compared with those of 774 oocytes from controls.


Main Outcome Measure(s):
Rate of metaphase II (MII) and morphologically abnormal oocytes.

The mean number of total and MII oocytes retrieved was significantly higher in the PCOM group. The rate of MII and morphologically abnormal oocytes was equivalent between the two groups. The mean number of embryos was significantly higher in the PCOM group. However, the percentage of top-quality embryos on day 3 was similar between the two groups. The implantation and clinical pregnancy rates were significantly higher in the PCOM group.

Polycystic ovarian morphology does not have a negative impact on the quality of oocytes and embryos or the outcome of IVF-ICSI.

  • Jason M. Franasiak

    Very interesting data. Was there any thought that, in excluding those with BMI >32 kg/m2 (average BMI in PCO group 23.5 kg/m2), you may be excluding those PCO patients with true metabolic syndrome who may have altered IGF1 that might in turn alter oocyte quality and ultimately embryo performance?

Translate »